Division of Cardiology, University of California, Los Angeles, CA, USA.
Am J Cardiol. 2010 Apr 15;105(8):1076-82. doi: 10.1016/j.amjcard.2009.12.006. Epub 2010 Feb 20.
This meta-analysis was undertaken to assess the efficacy and safety of drug-eluting stents (DESs) compared to bare metal stents (BMSs) in saphenous vein graft (SVG) interventions. DESs decrease the risk of target vessel revascularization in native coronary arteries compared to BMSs. The ideal treatment strategy in patients with SVG disease is unknown. A search of the published reports was conducted to identify studies that compared DESs and BMSs in SVG intervention with a minimum follow-up of 6 months. A total of 19 studies (2 randomized trials and 17 registries), including 3,420 patients who had undergone SVG intervention (DESs, n = 1,489 and BMS, n = 1,931), met the selection criteria. The mean length of follow-up was 20 + or - 12 months. Using the fixed effect model, target vessel revascularization was less frequently performed in patients who had undergone SVG intervention with a DES than with a BMS (odds ratio [OR] 0.59, 95% confidence interval [CI] 0.49 to 0.72). The incidence of myocardial infarction was lower in patients with a DES than in those with a BMS (OR 0.69, 95% CI 0.49 to 0.99). No differences were found in the risk of death (OR 0.78, 95% CI 0.59 to 1.02) or stent thrombosis (OR 0.41, 95% CI 0.15 to 1.11) between the 2 groups. In conclusion, these findings support the use of DESs in SVG lesions.
这项荟萃分析旨在评估药物洗脱支架(DES)与金属裸支架(BMS)在治疗静脉桥血管(SVG)病变中的疗效和安全性。与 BMS 相比,DES 可降低原发性冠状动脉靶血管血运重建的风险。对于 SVG 病变患者,理想的治疗策略尚不清楚。我们对已发表的研究进行了检索,以确定比较 DES 和 BMS 治疗 SVG 病变且随访时间至少 6 个月的研究。共有 19 项研究(2 项随机试验和 17 项注册研究),包括 3420 例接受 SVG 介入治疗的患者(DES 组 n = 1489 例,BMS 组 n = 1931 例),符合入选标准。平均随访时间为 20±12 个月。采用固定效应模型,DES 治疗组的靶血管血运重建发生率低于 BMS 治疗组(比值比[OR] 0.59,95%置信区间[CI] 0.49 至 0.72)。DES 组的心肌梗死发生率低于 BMS 组(OR 0.69,95%CI 0.49 至 0.99)。两组间死亡率(OR 0.78,95%CI 0.59 至 1.02)或支架血栓形成(OR 0.41,95%CI 0.15 至 1.11)的风险无差异。综上所述,这些发现支持在 SVG 病变中使用 DES。